SCHEMBL3318883

SCHEMBL3318883

CCC(CC)C(c1ccnn1-c1ccccc1)N(C)S(=O)(=O)c1cc(Cl)c(Cl)s1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C18 P33260 10/20 0.35
CYP2C9 P11712 10/20 0.35
CYP2C19 P33261 6/20 0.35
CYP2C8 P10632 9/20 0.35
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
GAA P10253 1/20 0.32
PTGES2 Q9H7Z7 1/20 0.32
HTR6 P50406 1/20 0.31
PTGER3 P43115 1/20 0.30
GUSB P08236 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3320494 0.86 PSEN1 (0.42) CYP2C18CYP2C9CYP2C19CYP2C8PSEN1
SCHEMBL3319766 0.82 CYP2C18 (0.41) CYP2C18CYP2C9CYP2C19CYP2C8PSEN1
SCHEMBL3319521 0.82 KMT2A (0.39) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL3323410 0.81 CYP2C18 (0.46) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL3317868 0.79 PSEN1 (0.50) CYP2C18CYP2C9CYP2C19CYP2C8PSEN1
SCHEMBL3322197 0.74 CYP2C18 (0.43) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL27658539 0.73 CYP2C18 (0.46) CYP2C18CYP2C9CYP2C19CYP2C8
SCHEMBL27678446 0.72 CYP2C18 (0.40) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1
SCHEMBL3318127 0.67 PSEN1 (0.64) CYP2C9CYP2C19PSEN1PSEN2APH1B
SCHEMBL27678450 0.66 CYP2C18 (0.40) CYP2C18CYP2C9CYP2C19CYP2C8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US claimed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP claimed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US claimed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US claimed
JP-2007517905-A 2007-07-05 JP claimed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP claimed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO claimed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US claimed
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US disclosed
US-7674813-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2010-03-09 US disclosed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP disclosed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US disclosed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US disclosed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP disclosed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO disclosed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole APP, IAPP, PARK7 CYP2C18 1381/4885CYP2C9 726/4885CYP2C19 1431/4885
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE APP, IAPP, PARK7 CYP2C18 1381/4885CYP2C9 726/4885CYP2C19 1431/4885
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole IAPP, APP, CBR3 CYP2C18 1342/4885CYP2C9 487/4885CYP2C19 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.